Introduction. Mothers at risk of preterm birth are treated with antenatal corticosteroids, which have advantageous effects for prematurely born infants. Accelerated villous maturation in the placenta is also associated with improved perinatal outcome. The primary aim of this study was to examine the association between antenatal corticosteroids and accelerated villous maturation. The secondary aim was to study associations with other placental pathologies. Material and methods. A retrospective cohort study including 105 women who had (n = 75) or had not (n = 30) been treated with antenatal corticosteroids. The women gave birth between 22 +0 and 26 +6 weeks of gestation in Stockholm County between 1 April 2004 and 31 March 2007. A pathologist blinded to all clinical data except gestational age examined the placental slides to identify pathology parameters. The outcomes were correlated with antenatal corticosteroid treatment, and confounding factors were adjusted using logistic regression. Results. Accelerated villous maturation was significantly higher in the group treated with corticosteroids (odds ratio 16, 95% CI 2.4-690, p = 0.0005). After adjustment for gestational age and preeclampsia, the difference remained significant (odds ratio 8.9, 95% CI 1.2-389, p = 0.021). No significant associations were found regarding the secondary outcome variables, after adjusting for possible confounders. Conclusions. Antenatal corticosteroid treatment before preterm birth is associated with accelerated villous maturation. This could be one of the pathways by which corticosteroids are beneficial for preterm infants.
Introduction
Preterm birth is the leading cause of perinatal mortality and morbidity (1, 2) . To improve the prognosis for preterm infants, women at risk of preterm birth are treated with antenatal corticosteroids (3, 4) , which have several advantageous effects (4, 5) . The most established effects are accelerated maturation of the fetal lungs and increased production of surfactant (4, 5) . The side effects
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Antenatal corticosteroids are frequently used to improve outcomes for premature infants. Our results show that this treatment is associated with accelerated villous maturation, which could partly explain why antenatal corticosteroids are beneficial for premature infants.
that may occur if the treatment is repeated are decreased birthweight and placental weight (6) . Antenatal corticosteroids may increase umbilical artery blood flow (7) , and it has previously been suggested that the placental villi could be a target for their effect (8) .
The placental villi develop throughout pregnancy: in the beginning, they are large and few in number, and at term, they are numerous, well branched and more vascularized (9) . In some placentas, the villi evolve during the second and early third trimesters into a stage that mimics the villi seen in placentas at term, a feature called accelerated villous maturation (10) . This pathological morphology is more common in placentas from pregnancies in which the mothers were diagnosed with complications associated with decreased perfusion of the placental bed, such as preeclampsia or hypertension (10) (11) (12) . Nevertheless, we have previously shown that accelerated villous maturation is also associated with enhanced blood flow in the umbilical cord and improved perinatal outcome (11, 13) , suggesting that this might be a compensatory action of the placenta under certain conditions.
As antenatal corticosteroids are frequently used (5) , an understanding of their effects on the fetus and the placenta is essential. The primary aim of this study was to determine whether antenatal corticosteroids are associated with accelerated maturation of the placental villi. A secondary aim was to identify the presence of associations with other placental pathology.
Material and methods
The cohort of this study consisted of all women who gave birth to singleton live-born infants between 22 +0 and 26
+6
weeks of gestation between 1 April 2004 and 31 March 2007, within Stockholm County. This study group is part of a previously presented cohort in which we studied perinatal outcomes in relation to placental pathology (13) . Women were excluded if the placenta was not examined. The mothers were divided into two groups: those who were treated with antenatal corticosteroids and those who were not. At gestational weeks 17-19 according to last menstruation, an ultrasound was performed to measure the fetus. The gestational age of the infant was then determined according to the ultrasound. This routine examination is offered to all pregnant women and is free of charge (14) .
The characteristics of the mothers and the infants and information about treatment with antenatal corticosteroids were collected from medical records. Preeclampsia was defined as systolic blood pressure > 140 mmHg and/ or diastolic blood pressure > 90 mmHg on two occasions at least 6 hours apart plus proteinuria, which was defined as > 0.3 g protein in a 24-h urine specimen (15) . Smallfor-gestational-age was defined as a birthweight < 2 standard deviations (SD) below the gestational age at birth according to Swedish growth charts (16) . Neonatal death was defined as death within the first 28 days after delivery, including death in the delivery room.
Antenatal corticosteroid treatment was provided according to current routines at the hospitals. Two 12-mg doses were administered via intramuscular injection (Betapred â , betamethasone; Swedish Orphan Biovitrum AB, Stockholm, Sweden) 12-24 h apart. There were no absolute contraindications for treatment with antenatal corticosteroids. Antenatal corticosteroids were not administered if there was not adequate time before the infant was delivered or if the delivery occurred before 23 +0 weeks of gestational age, according to current routines at the hospitals.
The fresh placentas were sent to the Section of Perinatal Pathology at Karolinska University Hospital Huddinge. The placentas were examined macroscopically, which included assessment of the shape, measurement of the diameter and inspection of the maternal and fetal surfaces, membranes and umbilical cord. The placentas were fixed in formalin, the umbilical cords and membranes were removed, and then the placentas were weighed. Two or three samples of both the fetal and maternal sides were taken from the normal-appearing parts of the placentas, and additional samples were taken from any abnormal appearing part. A total of one or two samples were taken from the umbilical cord, and one or two samples were taken from the membranes. The tissue samples were embedded in paraffin and stained with hematoxylin & eosin according to standard procedures. The examinations of the placental slides were performed by a senior pathologist specializing in perinatal pathology. The same pathologist studied all the placental slides and was blinded to all clinical data apart from gestational age.
The tissue samples from the placentas were studied microscopically to determine the maturation of the villi. In these examinations, the size and configuration of the villi, the number and architecture of the vessels within the villi, and the layers of trophoblasts were assessed. The microscopic appearance of the placental villi was correlated with the gestational age, resulting in three different outcomes: accelerated, normal or retarded maturation (see Figure 1a , b). The maturation of the villi was defined as accelerated if > 50% of the examined villi were more mature than normal for the gestational week; in some cases of accelerated maturation, there was a predominance of tertiary, term villi with well-developed syncytiovascular membranes and syncytial knotting; in other cases, the picture more closely resembled local distal villous hypoplasia. Maturation of the villi was not evaluated close to an infarction or thrombosis.
Chorioamnionitis was diagnosed histologically. The degree ranged from the presence of polymorphonuclear leukocytes at the subchorionic plate or lower third of chorion to extensive leukocyte infiltration in the chorioamnion, with necrosis of the amniotic epithelium or microabscess formation. Placental abruption was diagnosed either clinically or histopathologically, as previously described (13) . Fetal thrombosis, placental infarction, intervillous thrombosis, decidual arteriopathy and villitis were also defined as previously described (13) .
The placental weight was classified as low or high when it was below or above the 10th centile of the mean weight at the actual gestational age, respectively (17) . The coiling index was calculated by dividing the number of coils by the length of the umbilical cord in centimeters. Hypocoiling was defined as an index < 0.07 coils/cm, and hypercoiling was defined as an index > 0.30 coils/cm (18) . Abnormal cord insertion was defined as velamentous or marginal insertion.
The statistical analyses were performed with the statistical program IBM SPSS STATISTICS v. 23 (IBM Corp., Armonk, NY, USA) and SAS 9.4 (SAS Institute, Cary, NC, USA). The placental pathology of the two study groups adjusted for gestational age was analyzed with logistic regression. When appropriate, adjustments were also made for preeclampsia. The statistical results are presented as p-values, odds ratios (OR) with 95% CI and/or adjusted odds ratios with 95% CI. For the continuous variables, an independent t-test was used. For categorical variables, a chi-squared test was performed. Statistical significance was defined as p < 0.05.
Ethical approval
Ethical permission was obtained on 27 August 2014, from the Ethics Committee of Stockholm, with the registration number 2014/1277-31/4.
Results
The results of the cohort recruitment process are described in a flow chart in Figure 2 . The characteristics of the two study groups are shown in Table 1 . The two study groups were similar in terms of maternal age, maternal body mass index, fetal sex, and children born small-for-gestational-age. The fetal sex was unknown in one case. The only statistically significant differences between the study groups were gestational age at birth (p = 0.002) and neonatal mortality (p < 0.001). There was a difference in mean birthweight between the groups, which was presumably due to the difference in gestational age, as the proportion of infants born small-for-gestational-age was similar in both groups. This difference was not significant. In the 34 cases that were excluded due to absent placental examination, the mean gestational age was 25 +2 weeks, and the mean birthweight was 805 g. Of the 75 women receiving treatment with antenatal corticosteroids, 18 received one dose, 55 received two doses, one received three doses, and for one woman, the number of doses was unknown. One woman received the two doses < 12 h apart, 28 women received two doses 12-23 h apart, and 26 women received doses ≥ 24 h apart. The average time from the first dose of antenatal corticosteroids to delivery was 6 days, ranging from 1 h to 27 days. In one case, the timing of the corticosteroid treatment was unknown. Twenty-seven placentas in the group treated with antenatal corticosteroids presented accelerated villous maturation, as did one placenta in the untreated group. Accelerated villous maturation was significantly more common in the group treated with antenatal corticosteroids (p = 0.0005), and the results were still significant after adjusting for gestational age and preeclampsia (p = 0.021) ( Table 2 ). Regarding the time between treatment and delivery in relation to the presence of accelerated villous maturation, the effect of treatment was evident immediately, although the number of placentas with accelerated villous maturation increased as the time since treatment increased. This is illustrated in Figure 3 .
Fetal thrombosis was found in 13 (17.3%) cases in the group treated with antenatal corticosteroids and in only one (3.3%) case in the non-treated group, but the difference only showed a trend towards a statistically significant difference (p = 0.089) ( Table 2) . After adjustment for possible confounders, the difference disappeared.
Additionally, chorioamnionitis showed a trend towards a difference, occurring in 62.7% in the group treated with antenatal corticosteroids and 80.0% in the untreated group; however, after adjustment for possible confounders, this difference also disappeared ( Table 2 ). Villitis was not found in any cases in either group.
Although the placental weight was low for gestational age in 18.7% of the group treated with antenatal corticosteroids, it was high for gestational age in 9.3% of the cases in the same group. The opposite pattern was observed for the untreated group (10% and 20%, respectively). However, the number of cases was limited and the difference was not statistically significant ( Table 2 ). The mean placental weight was 201.9 g (SD 53.8) in the treated group and 213.6 g (SD 79.1) in the non-treated group.
The group treated with antenatal corticosteroids had significantly fewer hypocoiled umbilical cords (p = 0.041), but after adjustment for confounding variables, only a trend towards a difference remained (p = 0.073) ( Table 2 ). In the treated group, the mean coiling index of the umbilical cord was 0.23 (SD 0.16), compared with 0.19 (SD 0.10) for the non-treated group. Data regarding coiling was incomplete in 33 cases. There was no difference in the frequency of abnormal cord insertions. In seven cases, an assessment of the insertion was missing. No differences were found regarding infarction, placental abruption, intervillous thrombosis or decidual arteriopathy (Table 2) . In both groups, only one case was found with no placental pathology, but in that placenta, coiling could not be assessed.
Discussion
Antenatal corticosteroids have a well-known effect on the premature lung, but the physiological explanation for decreases in mortality and morbidities such as necrotizing enterocolitis and intraventricular hemorrhage is not clear (1, 4, 5) . We have previously presented two studies indicating that accelerated villous maturation is associated with improved blood flow from the placenta and favorable outcomes for the infant (11, 13 ). In the current study, we show that accelerated villous maturation is significantly more common in a group treated with antenatal corticosteroids. We did not observe any statistically significant difference in secondary outcome variables after adjusting for possible confounders.
One weakness of the study is its design, which does not allow us to draw any conclusions regarding causality. The use of the current study design might also have introduced biases. However, it would not have been ethical to provide a placebo instead of antenatal corticosteroids to women at risk of preterm birth. Taking the risk of selection bias into account, we compared the mothers in the two groups in terms of several factors. Of these, gestational age differed between the groups, a finding that can be explained by the general routine of not treating women at risk of preterm birth with antenatal corticosteroids before 23 +0 weeks of gestation. Because of the difference in gestational age, we adjusted for its effect in the statistical analyses. Although the difference in preeclampsia was not significant, we chose to adjust for this complication when relevant as other studies have found that preeclampsia is associated with accelerated villous maturation and similar placental appearances, as well as other placental variables (11, 12) . There was also a difference in the rate of neonatal death between the two groups. This was expected, and the difference could be explained by the effect of the antenatal steroids on lung maturation and neonatal mortality. In addition, neonatal death is dependent on gestational age and, as there was a difference in age between the groups, this ought to affect the neonatal outcome.
A strength of the study was that the rate of exclusions due to absent placental examination was small (19) and the excluded cases broadly resembled the included ones. We therefore consider the cohort in our study to be representative of the study population.
Our results are supported by Ghidini et al. (8), who did not study accelerated villous maturation specifically but did examine several features of placental villi and suggested that the villi could be a precise target for the effects of antenatal corticosteroids (8) .
A study by Wallace and Baker (7) showed that treatment with antenatal corticosteroids may increase umbilical artery blood flow in pregnancies with an absent enddiastolic blood flow in the umbilical artery. The physiological explanation for this phenomenon is not known, but the authors suggested that the increased blood flow might be due to decreased vascular resistance in the placenta (7) . It remains to be established whether accelerated villous maturation could mediate this effect. We recently found that accelerated villous maturation was correlated with decreased resistance in the umbilical artery as measured by pulsatility index and blood flow class (11) . In addition to the possible effect on the blood flow, accelerated villous maturation might also mediate an improved diffusion capacity. As described earlier, accelerated villous maturation is characterized by a larger number of villi and a shorter distance between the fetal and maternal blood (10) . The decreased distance might facilitate the diffusion of nutrients and waste products (10) , which ought to improve the capacity for diffusion over the placental bed, something that could persist even longer than an improved blood flow.
Accelerated villous maturation is more often seen in placentas from women with preeclampsia (10) . Although the pathogenesis of preeclampsia is not fully clear, an incomplete invasion of trophoblasts into the decidual arteries is believed to result in placental hypoxia (20) . Nagamatsu et al. (21) have shown that a hypoxic environment can stimulate the placental villi to secrete soluble fms-like tyrosine kinase-1 (sFlt-1). Furthermore, overexpression of sFlt-1 has been related to accelerated villous maturation (22) . Hence, if treatment with antenatal corticosteroids stimulates the maturation of the placental villi, it might also result in an increase in sFlt-1. However, Nayeri et al. (23) did not find any changes in sFlt-1 that were dependent on treatment with corticosteroids. One explanation could be that the accelerated villous maturation related to hypoxia differs from accelerated villous maturation related to treatment with antenatal corticosteroids. Therefore, even though in previous studies, we observed better perinatal outcomes when accelerated villous maturation was present, the improved perinatal outcome cannot be extrapolated to pregnancies with accelerated villous maturation related to antenatal corticosteroids. To draw more definitive conclusions, further studies of neonatal outcomes related to accelerated villous maturation are required. Although a very recent study (24) showed that on a molecular level, the accelerated villi are of advanced age, indicating that those placentas could be affected by the premature activation of a normal maturational program, there is still a need for further studies investigating the mechanisms and pathogenesis of accelerated villous maturation, including gene expression studies, because this condition is not well understood.
Treatment with a single course of antenatal corticosteroids has not been associated with any short-or longterm fetal or neonatal adverse effects (25) . However, repeat doses given 7 days after an initial course of antenatal corticosteroids have been associated with decreased birthweight, body length, head circumference and placental weight (6, 26) . Although we did not observe a statistically significant difference in placental weight, we did see fewer placentas with a high weight and more placentas with a low weight in the treated group. Elfayomy and Almasry (6) first reported decreased placental weight after repeat doses of corticosteroids compared with a single dose and controls. The limited number of women in our study could explain the lack of significance and the low number of women who underwent repeat treatment.
If antenatal corticosteroids affect the maturation of the placental villi and potentially have a positive effect on placental function, the indication for treatment with antenatal corticosteroids could be widened. The steroids might have a beneficial effect on placentas and neonates affected by, or at risk of, different diseases related to abnormal placental perfusion, such as intrauterine growth restriction, intrauterine fetal death and preeclampsia, regardless of prematurity. Nonetheless, as a repeat course is associated with possible adverse effect on the growth of the fetus, an extension of indications for treatment, rather than a higher or more frequent dose, should primarily be considered.
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